Evidence map›Paper›PMID 39981348›Full record

ArticleFrontiers in cardiovascular medicine2025

A case series of patients with cardiac amyloidosis evaluated at a Colombian university hospital.

Juan David López-Ponce de León, Santiago Granados-Álvarez, Juan Pablo Arango-Ibanez, Juan Manuel Montero Echeverri, Andrea Alejandra Arteaga Tobar, Andrea Facio-Lince Garcia, Yorlany Rodas Cortes, Juan Esteban Gómez-Mesa

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juan David López-Ponce de LeónCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Santiago Granados-ÁlvarezFacultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
Juan Pablo Arango-IbanezCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Juan Manuel Montero EcheverriCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Andrea Alejandra Arteaga TobarCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Andrea Facio-Lince GarciaFacultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
Yorlany Rodas CortesCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Juan Esteban Gómez-MesaCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In Colombia, the characteristics of cardiac amyloidosis (CA)-including wild-type transthyretin amyloidosis (ATTRwt), immunoglobulin light chain amyloidosis (AL), and genetic variant transthyretin amyloidosis (ATTRv)-are underexplored. Methods: This case series at a Colombian university hospital analyzed demographic, clinical, laboratory, radiological, and genetic data of CA patients diagnosed between 2018 and 2022. Patients with incomplete data underwent further testing. Results: Of 24 identified patients, 14 were included after exclusions. The majority were male (73.3%), with an average age of 70.6 years. ATTRv and AL were equally prevalent (42.8%), followed by ATTRwt (14.2%). The p.Val142Ile TTR mutation was found among all ATTRv patients. Most presented with functional capacity NYHA I-II and common electrocardiographic findings included low voltage, atrial fibrillation, and first-degree AV block. Echocardiography and cardiac magnetic resonance imaging revealed ventricular hypertrophy, diastolic dysfunction, reduced longitudinal strain, and late myocardial enhancement. Conclusions: AL and ATTRv were the most common causes of CA followed by ATTRwt. This distribution, along with the clinical, and radiological characterization is consistent with previous reports of other regions. The p.Val142Ile mutation was the only one found in patients with ATTRv, suggesting a strong African genetic influence. These findings enhance our understanding of CA in the region.

Indexed as

AL amyloidosisamyloidosiscardiac amyloidosisColombiaLatin Americatransthyretin

Identifiers

PMID39981348
PMCPMC11841452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.